The article discusses the low utilization of FDA-approved treatments for opioid and alcohol use disorders, such as naloxone and naltrexone, despite the critical need for these medications. Experts like Dr. Nora Volkow and Dr. George Koob highlight that less than 2% of individuals with alcohol use disorder receive pharmacological treatment due to stigma and a general hesitation among physicians to address addiction. The article draws parallels with the effective rollout of GLP-1 medications for obesity, posing that similar innovative approaches might improve the treatment landscape for alcohol-related issues.
Obesity was stigmatized for decades, and most physicians didn't treat this disorder, other than telling patients to diet, until GLP-1 drugs like Ozempic arrived on the scene.
Dr. Koob emphasized < 2% of individuals with AUD receive pharmacological treatment, despite the availability of effective medications.
Many doctors hesitate to screen for and treat AUD, leading to patients being unaware of effective medication options.
Dr. Koob challenged focusing on abstinence, promoted by programs like Alcoholics Anonymous (AA), and suggested new treatment approaches.
Collection
[
|
...
]